This is not the most recent version of the article. View current version (8 NOV 2013)

Intervention Protocol

Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction

  1. Taghride Dahhan1,*,
  2. Eva Balkenende2,
  3. Madelon van Wely1,
  4. Sabine Linn3,
  5. Mariëtte Goddijn1

Editorial Group: Cochrane Menstrual Disorders and Subfertility Group

Published Online: 14 NOV 2012

Assessed as up-to-date: 27 AUG 2012

DOI: 10.1002/14651858.CD010240


How to Cite

Dahhan T, Balkenende E, van Wely M, Linn S, Goddijn M. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD010240. DOI: 10.1002/14651858.CD010240.

Author Information

  1. 1

    Academic Medical Centre, University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands

  2. 2

    Academic Medical Centre, University of Amsterdam, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands

  3. 3

    Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, Netherlands

*Taghride Dahhan, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands. t.dahhan@amc.uva.nl.

Publication History

  1. Publication Status: New
  2. Published Online: 14 NOV 2012

SEARCH

This is not the most recent version of the article. View current version (08 NOV 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effect of tamoxifen or letrozole in addition to standard controlled ovarian stimulation (COS) protocols on the breast cancer-free interval in premenopausal women with breast cancer who undergo COS for embryo or oocyte cryopreservation.